Children can be deeply affected when a beloved grandparent develops Alzheimer's disease. They may become afraid, confused, sad, angry, frustrated, worried, or embarrassed -- just to name a few potential feelings. Although each child reacts differently, there are some common fears:
1. The grandparent doesn't love them anymore
2. Their grandparent may be crazy
3. It's their fault that their grandparent is sick
4. They may catch the disease
5. Their parent(s) may get it
SIGNS THAT YOUR CHILD MAY BE HAVING PROBLEMS COPING
Massachusetts Gov. Deval Patrick, the Massachusetts Life Sciences Center and seven global biopharmaceutical companies announced on Wednesday the formation of the Massachusetts Neuroscience Consortium. The announcement took place in the Massachusetts Pavilion at the 2012 BIO International Convention. Speakers included Patrick; Susan Windham-Bannister, president & CEO of the Massachusetts Life Sciences Center; James Hoyes, president, EMD Serono; Jeffrey Flier, Dean of Harvard Medical School; and patients.
The Working Mother Research Institute surveyed nearly 2,500 women, including more than 1,200 who have cared for a loved one with Alzheimer's, to get a clear picture of how the responsibility of caregiving affects their emotional, financial and work lives, as well as their families.
It seemed as if it would be a perfectly ordinary occasion, that hot August day in 1959. Three generations of a large Oklahoma family gathered at a studio in nearby Perryton, Tex., to have a photo taken of the elders, 14 siblings ranging in age from 29 to 52. Afterward, everyone went to a nearby park for a picnic.
Dementia is thought of as a scourge of the developed world, with its aging population, but it actually may occur at an even higher rate in developing countries, or so, at least, report researchers led by Martin Prince at King's College London U.K., in the May 23 Lancet. A shift in these countries' populations toward aging, combined with low education and undercounting, is blamed for the finding.
The Food and Drug Administration (FDA) approved on April 10th a brain imaging method for individuals who are being evaluated for Alzheimer's Disease (AD) or other causes of progressive cognitive impairment. The new method uses a drug called Amyvid (also known as Florbetapir or AV-45) along with Positron Emission Tomography (PET). MGH ADRC researchers were co-investigators for the clinical trial in which Amyvid was developed and have used this and other, similar PET methods for research purposes since 2005.
Two research studies, co-led by UC Davis neurologist Charles DeCarli and conducted by an international team that included more than 80 scientists at 71 institutions in eight countries, has advanced understanding of the genetic components of Alzheimer's disease and of brain development. Both studies appear in the April 15 edition of the journal Nature Genetics.
The Food and Drug Administration (FDA) has approved Amyvid (florbetapir F18 injection), Avid Pharmaceuticals/Eli Lilly and Company's positron emission tomography (PET) tracer, for A-Beta plaque imaging in cognitively impaired patients being clinically evaluated for Alzheimer's disease. The compound will be available for use in June, with the aim of helping researchers rule out - not diagnose - the disease.